Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

gainst products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative.  Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. 

Contacts:

Onyx Pharmaceuticals, Inc.
Danielle Bertrand (media)
1-650-266-2114

Amgen
Ashleigh Koss, 1-805-313-6151 (media)
Arvind Sood, 1-805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20131107/LA12955LOGO)


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... (PRWEB) November 24, 2014 2014 ... Dihydrazide Industry is a professional and in-depth research ... Adipic Dihydrazide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/23/2014)... St. Francis, WI (PRWEB) November 23, 2014 ... based manufacturer and supplier of fine chemical ingredients ... industries announced the launch of its new website, ... a description of Apiscent Labs, clean design, easy ... qualities that make Apiscent Labs stand out. ...
(Date:11/22/2014)... 2014 CannLabs, Inc. (OTCQB: ... and scientific testing methodologies relating to cannabis, today announced ... line of credit from an existing stockholder of the ... secured this commitment from one of our existing stockholders,” ... “This capital will help accelerate our planned expansions into ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Respiratory ... simulate the proper management of life-like respiratory ailments ... lung devices . Grand Rapids-based, Michigan Instruments Inc. ... donate two of the respiratory simulation units to ... each. Grand Valley and Muskegon Community College are ...
Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3CannLabs Secures $750,000 Line Of Credit 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... Strategic Development of the Company,s National Network of ... Healthplace America, the country,s first and only ... services of Robert A. Yungk as Chief Strategy ... ensuring the company,s participating Healthplace Surgery Benefit(TM) providers ...
... exclusive access to, the global ... Biosystems Inc. (MBX:TSX) announced today that the Company ... based on discoveries arising from its extensive work ... The new technology represents a significant departure from ...
... /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China Sky ... CSKI ), a,leading fully integrated pharmaceutical company producing,over-the-counter ... today,announced that an extension notification filed with the ... Form 10-K on March 31, 2009, is,related to ...
Cached Biology Technology:Healthplace America Engages Robert A. Yungk to Provide Services as Chief Strategy Officer 2Microbix Announces A New Technology Platform For The SST Project 2Microbix Announces A New Technology Platform For The SST Project 3China Sky One Medical, Inc. Provides Update on Filing Form 10-K 2China Sky One Medical, Inc. Provides Update on Filing Form 10-K 3
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... --   3D scanner developer ... Fuel3D , a developer of 3D scanning solutions, today ... million (£4 million). This funding builds on the company,s initial ... paves the way for the commercial launch of the company,s ... was led by Chimera Partners and will be used to ...
(Date:11/3/2014)... published in this month,s Proceedings of the ... a recently discovered communication molecule of the body,s immune ... to limit inflammation and the current study reports its ... ability of the immune system to recognize and target ... effect on the immune system now allows us to ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... The Scripps Research Institute has received funding from the ... T. Valente, an assistant professor in the Department of ... study of the many genes and protein products that ... inside human cells. These unique molecular interactions between retrovirus ...
... 26, 2010 Periodontitis, a common inflammatory disease in ... of bacteria and potential bone and tooth loss. Although ... strategies target the inflammatory response. In an article in ... American Dietetic Association , researchers from Harvard Medical School ...
... While most commonly associated with mononucleosis, Epstein-Barr virus (EBV) ... after the initial infection takes place, including some forms of ... Biological Chemistry , scientists at The Wistar Institute describe how ... effects of gene activity allows EBV to hide within ...
Cached Biology News:Landenberger Foundation awards grant to Scripps Florida scientist to study HIV 2Consuming polyunsaturated fatty acids may lower the incidence of gum disease 2MicroRNAs dictate the Epstein-Barr virus' elaborate waiting game, cancer formation 2MicroRNAs dictate the Epstein-Barr virus' elaborate waiting game, cancer formation 3
Purified anti-human CD182 (CXCR2)...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Request Info...
Polyclonal Antibody to SHPRH...
Biology Products: